Based in Glasgow, UK, Sistemic Ltd. is a company that specializes in microRNA-based services and kit-based products. Cynata Therapeutics is a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP).
Cynata’s Cymerus™ technology utilizes iPSCs originating from an adult donor as the starting material for generating mesenchymal stem cells (MSCs). The importance of this technology is that it is a process for manufacturing a consistent cell therapy product.
Cynata’s lead product is CYP-oo1, an iPSC-derived mesenchymal stem cell product that is anticipated to be the world’s first allogeneic iPSC product to enter a clinical trial.
In the press release below, Sistemic Ltd. and Cynata Therapeutics announce that they have entered into an agreement in which Sistemic will use its miRNA technology platforms to develop an in-process assessment assay for Cynata’s Cymerus™ cell therapy products.
MSCs are currently being explored in nearly 500 clinical trials worldwide, but technologies supporting large-scale manufacturing of MSCs are scare, which is what makes standardization and scale-up of the Cymerus technology important.
To learn more, read the full press release issued by Sistemic Ltd. below. [Read more…]
